

Immuno- --- *genetics*

Editor-in-chief

GEORGE D. SNELL, Bar Harbor, Maine

Managing Editor

JAN KLEIN, Dallas, Texas

Associate Editors

B. BENACERRAF, Boston, Massachusetts

H.O. MCDEVITT, Stanford, California

N.A. MITCHISON, London, U.K.

J.W. UHR, Dallas, Texas

Editorial Board

D.W. BAILEY, Bar Harbor, Maine
D. BENNETT, New York, New York
J.D. CAPRA, Dallas, Texas
N. COHEN, Rochester, New York
J. DAUSSET, Paris, France
P. DÉMANT, Amsterdam, The Netherlands
M. EDIDIN, Baltimore, Maryland
J.K. EGOROV, Moscow, U.S.S.R.
J. FORMAN, Dallas, Texas
D.L. GASSER, Philadelphia, Pennsylvania
D. GÖTZE, Philadelphia, Pennsylvania
W.H. HILDEMAN, Los Angeles,
California
N. HILSCHMANN, Göttingen, Germany
P. IVÁNYI, Amsterdam, The Netherlands
E. KLEIN, Stockholm, Sweden
B.B. KNOWLES, Philadelphia, Pennsylvania

F.M. KOURILSKY, Paris, France
F. LILLY, New York, New York
V. MIGGIANO, Basle, Switzerland
E. MOZES, Rehovot, Israel
S.G. NATHENSON, New York, New York
L. DUPASQUIER, Basle, Switzerland
K. RAJEWSKY, Cologne, Germany
H. RAMSEIER, Zurich, Switzerland
R.A. REISFELD, La Jolla, California
M. SELA, Rehovot, Israel
D.C. SHREFFLER, St. Louis, Missouri
A.G. STEINBERG, Cleveland, Ohio
H. WAGNER, Mainz, Germany
N.L. WARNER, Albuquerque, New Mexico
D.B. WILSON, Philadelphia, Pennsylvania
R.M. ZINKERNAGEL, La Jolla, California



Springer-Verlag
New York Heidelberg Berlin

Index

Beals, T.F.: <i>see</i> Schultz, J.S. <i>et al.</i>	315
Beisel, K.W.: <i>see</i> Passmore, H.C.	393
Benaceraff, B.: <i>see</i> Cheung, N.K.V. <i>et al.</i>	163
Benedict, A.A., Pollard, L.W., and Maurer, P.H.: Genetic Control of Immune Responses in Chickens II. Responses to Methylated Bovine Serum Albumin-poly(Glu ⁶⁰ Ala ³⁰ Tyr ¹⁰) _n Aggregates	199
Bertrams, J.: <i>see</i> Grosse-Wilde, H. <i>et al.</i>	481
Bevan, M.J., and Hyman, R.: The Ability of H-2 ⁺ and H-2 ⁻ Cell Lines to Induce or be Lysed by Cytotoxic T Cells	7
Black, G.: <i>see</i> Palm, J. <i>et al.</i>	79
Boyse, E.A.: <i>see</i> Flaherty, L. <i>et al.</i>	101
Boyse, E.A.: <i>see</i> Koo, G.C. <i>et al.</i>	213
Boyse, E.A.: <i>see</i> Sato, H. <i>et al.</i>	591
Brézin, C.: <i>see</i> Cazenave, P. <i>et al.</i>	489
Briles, D.E., Krause, R.M., and Davie, J.M.: Immune Response Deficiency of BSVS Mice. I. Identification of Ir Gene Differences Between A/J and BSVS Mice in the Antistreptococcal Group A Carbohydrate Response	381
Cazenave, P., Brézin, C., Puget, A., and Mandy, W.J.: Lagomorph-Constant Region IgG Allotypes: Shared e Determinants in Ochotona Sp.	489
Cherry, J.D.: <i>see</i> Spencer, M.J. <i>et al.</i>	365
Cheung, N.K.V., Dorf, M.E., and Benaceraff, B.: Genetic Control of the Primary Humoral Response to Glu ⁵⁶ Lys ³⁵ Phe ⁹	163
Clark, E.A., and Hildemann, W.H.: Genetics of Graft-Versus-Host Reactions I. Production of Splenomegaly and Mortality in Mice Disparate at <i>H-2I</i> Subregions	281
Clark, E.A.: <i>see</i> Harmon, R.C. <i>et al.</i>	601
Cukrová, V., Rychlíková, M., and Démant, P.: Defective MLR Capacitation in the Human: Low Xenogeneic MLR Capacity Associated with HLA Antigens AW25 B18, and DW2	531

Davie, J.M.: <i>see</i> Briles, D.E. <i>et al.</i>	381
Démant, P.: <i>see</i> Cukrová, V. <i>et al.</i>	531
Démant, P.: <i>see</i> Morello, D. <i>et al.</i>	349
DeMott-Friberg, R.: <i>see</i> Schultz, J.S. <i>et al.</i>	315
Dorf, M.E.: <i>see</i> Cheung, N.K.V. <i>et al.</i>	163
Dupont, B.: <i>see</i> Hansen, J.A. <i>et al.</i>	327
Edidin, M.: <i>see</i> Ostrand-Rosenberg, S. <i>et al.</i>	127
Elkins, W.L., and Silvers, W.K.: Variable Effect of an <i>H-2I</i> Barrier on Response to Skin Allografts in the Mouse.	245
Ertl, H.C.J., Gerike, R.H.W., and Koszinowski, U.H.: Virus-Specific T-Cell Sensitization. Requirements for Vaccinia Virus-Specific T-Cell Sensitization in vivo	515
Figuroa, F.: <i>see</i> Pizarro, O. <i>et al.</i>	57
Flaherty, L., Stanton, T.H., and Boyse, E.A.: Contamination of Ia Antiserum A.TL anti-A.TH with Antibodies Related to the <i>Tla</i> Region.	101
Forman, J., and Klein, J.: Immunogenetic Analysis of <i>H-2</i> Mutations VI. Crossreactivity in Cell-Mediated Lympholysis Between TNP-Modified Cells from <i>H-2</i> Mutant Strains	183
Friedrich, U.: <i>see</i> Zeuthen, J. <i>et al.</i>	567
Gamble, J.R.: <i>see</i> Vadas, M.A. <i>et al.</i>	137
Gerike, R.H.W.: <i>see</i> Ertl, H.C.J. <i>et al.</i>	515
Gewurz, H.: <i>see</i> Osofsky, S.G. <i>et al.</i>	195
Gladstone, P.: <i>see</i> Pious, D. <i>et al.</i>	437
Good, R.A.: <i>see</i> Hansen, J.A. <i>et al.</i>	327
Götze, D.: <i>see</i> Nowack, H. <i>et al.</i>	177
Gregorová, S., Iványi, P., Šimonová, D., and Micková, M.: <i>H-2</i> -Associated Differences in Androgen-Influenced Organ Weights of A and C57BL/10 Mouse Strains and their Crosses	301
Grosse-Wilde, H., Bertrams, J., Schuppien, W., Netzel, B., Ruppelt, W., and Kuwert, E.K.: HLA-D Typing in 111 Multiple Sclerosis Patients: Distribution of Four HLA-D Alleles	481
Grosse-Wilde, H.: <i>see</i> Hauptmann, G. <i>et al.</i>	557
Grumet, F.C.: <i>see</i> Smith, S.M. <i>et al.</i>	221
Hammerberg, C.: <i>see</i> Ostrand-Rosenberg, S. <i>et al.</i>	127
Hansen, J.A., Dupont, B., L'Esperance, P., and Good, R.A.: Congenital Neutropenia: Abnormal Neutrophil Differentiation Associated with <i>HLA</i>	327
Harmon, R.C., Clark, E.A., O'Toole, C., and Wicker, L.S.: Resistance of <i>H-2</i> Heterozygous Mice to Parental Tumors. I. Hybrid Resistance and Natural Cytotoxicity to EL-4 Are Controlled by the <i>H-2D-Hh-1</i> Region	601
Hašek, M.: <i>see</i> Holář, V.	155
Haughton, G.: <i>see</i> Wettstein, P.J.	65
Hauptmann, G., Tongio, M.M., Grosse-Wilde, H., and Mayer, S.: Linkage Between C2 Deficiency and the <i>HLA-A10, B18, Dw2/BfS</i> Haplotype in a French Family	557
Helgesen, A.: <i>see</i> Kaakinen, A. <i>et al.</i>	205

Heyner, S.: <i>sse</i> Zink, G.L.	257
Hildemann, W.H.: <i>see</i> Clark, E.A.	281
Holáň, V., and Hašek, M.: Specificity of Cell-Mediated Transplantation Reactions in Rats Detected by the Macrophage Adherence Inhibition Test	155
Hyman, R., and Stallings, V.: Analysis of Hybrids Between an H-2 ⁺ , TL ⁻ Lymphoma and an H-2 ⁺ , TL ⁺ Lymphoma and Its H-2 ⁻ , TL ⁻ Variation Subline	171
Hyman, R.: <i>see</i> Bevan, M.J.	7
Itakura, K.: <i>see</i> Sato, H. <i>et al.</i>	591
Iványi, P.: <i>see</i> Gregorová, S. <i>et al.</i>	301
Jackson, D.C., Parish, C.R., and McKenzie, I.F.C.: Detection and Isolation of an Ia Glycoprotein Antigen from Mouse Serum	267
Kaakinen, A., Helgesen, A., Nousiainen, H., Solheim, B.G., and Thorsby, E.: The HLA-D Determinants. A Population Study of Norwegians	205
Kappler, J.W.: <i>see</i> Marrack, P.	541
Keat, A.C.: <i>see</i> Pegrum, G.D. <i>et al.</i>	523
Kim, Y.T., and Siskind, G.W.: Studies on the Control of Antibody Synthesis X. Selective Breeding of Rats for the Production of High-Affinity Antibody	463
Klein, E.: <i>see</i> Zeuthen, J. <i>et al.</i>	567
Klein, J.: <i>see</i> Forman, J.	183
Klein, J.: <i>see</i> Zinkernagel, R.M.	581
Kohn, H.I.: <i>see</i> McKenzie, I.F.C. <i>et al.</i>	333
Koo, G.C., Mittl, L.R., and Boyse, E.A.: Antibody to Testicular Cells in the Serum of Normal Mice	213
Koszinowski, U.H.: <i>see</i> Ertl, H.C.J. <i>et al.</i>	515
Krause, R.M.: <i>see</i> Briles, D.E. <i>et al.</i>	381
Kuwert, E.K.: <i>see</i> Grosse-Wilde, H. <i>et al.</i>	481
Lane, D.P.: <i>see</i> Silver, D.M.	295
Leslie, G.A.: <i>see</i> Stankus, R.P.	233
L'Esperance, P.: <i>see</i> Hansen, J.A. <i>et al.</i>	327
Lewis, C.M.: <i>see</i> Pegrum, G.D. <i>et al.</i>	523
Lonai, P., and McDevitt, H.O.: The Expression of <i>I</i> -Region Gene Products on Lymphocytes I. Demonstration of MLR Determinants on T Cells	17
Lonai, P., and McDevitt, H.O.: The Expression of <i>I</i> -Region Gene Products on Lymphocytes II. Genetic Localization and Cellular Distribution of MLR Determinants.	33
Mandy, W.J.: <i>see</i> Cazenave, P. <i>et al.</i>	489
Marcy, S.M.: <i>see</i> Spencer, M.J. <i>et al.</i>	365
Marrack, P., and Kappler, J.W.: Anti-Ia Inhibits the Activity of B Cells But Not a T Cell-Derived Helper Mediator	541
Maurer, P.H.: <i>see</i> Benedict, A.A. <i>et al.</i>	199
Maurer, P.H.: <i>see</i> Merryman, C.F. <i>et al.</i>	373
Mayer, S.: <i>see</i> Hauptmann, G. <i>et al.</i>	557
McDevitt, H.O.: <i>see</i> Lonai, P.	17, 33
McKenzie, I.F.C., Morgan, G.M., Melvold, R.W., and Kohn, H.I.: BALB/	

c- <i>H-2^{db}</i> : A New <i>H-2</i> Mutant in BALB/cKh that Identifies a Locus Associated with the <i>D</i> Region	333
McKenzie, I.F.C.: <i>see</i> Jackson, D.C. <i>et al.</i>	267
Melvold, R.W.: <i>see</i> McKenzie, I.F.C. <i>et al.</i>	333
Merryman, C.F., Maurer, P.H., and Zeiger, A.R.: Genetic Control of Two Independently Segregating Loci in Mice to the Sequential Polypeptide (Tyr-Ala-Glu-Gly) _n	373
Mickey, M.R.: <i>see</i> Spencer, M.J. <i>et al.</i>	365
Micková, M.: <i>see</i> Gregorová, S. <i>et al.</i>	301
Miller, J.F.A.P.: <i>see</i> Vadas, M.A. <i>et al.</i>	137
Mittl, L.R.: <i>see</i> Koo, G.C. <i>et al.</i>	213
Mittal, K.K.: <i>see</i> Osofsky, S.G. <i>et al.</i>	195
Morello, D., Neauport-Sautes, C., and Démant, P.: Topographical Relationships Among <i>H-2</i> Specificities Controlled by the <i>D</i> Region	349
Morgan, G.M.: <i>see</i> McKenzie, I.F.C. <i>et al.</i>	333
Murphy, G.: <i>see</i> Silvers, W.K. <i>et al.</i>	85
Neauport-Sautes, C.: <i>see</i> Morello, D. <i>et al.</i>	349
Ness, D.B.: <i>see</i> Smith, S.M. <i>et al.</i>	221
Netzel, B.: <i>see</i> Grosse-Wilde, H. <i>et al.</i>	481
Newton, R.C., and Warner, C.M.: The Immune Response of Inbred Mouse Strains to DNP-BGG. 1. The Effect of Dose and Adjuvant	449
Nousiainen, H.: <i>see</i> Kaakinen, A. <i>et al.</i>	205
Nowack, H., Rohde, H., Götze, D., and Timpl, R.: Genetic Control and Carrier and Suppressor Effects in the Antibody Response of Mice to Procollagen	117
Osofsky, S.G., Thompson, B.H., Gewurz, H., Schmid, F.R., and Mittal, K.K.: Evidence for Lack of Linkage Between HLA and C3 Deficiency in Man	195
Ostrand-Rosenberg, S., Hammerberg, C., Edidin, M., and Sherman, M.I.: Expression of <i>Histocompatibility-2</i> Antigens on Cultured Cell Lines Derived from Mouse Blastocysts	127
O-Toole, C.: <i>see</i> Harmon, R.C. <i>et al.</i>	601
Palm, J., Rigiero, C., and Black, G.: Further Studies on the Number of Histocompatibility Loci in Rats	79
Parish, C.R.: <i>see</i> Jackson, D.C. <i>et al.</i>	267
Passmore, H.C., and Beisel, K.W.: Preparation of Antisera for the Detection of the Ss Protein and the Slp Alloantigen	393
Pegrum, G.D., Lewis, C.M., and Keat, A.C.: HLA Antigens Associated with the Lymphocyte Nucleus	523
Pious, D., Soderland, C., and Gladstone, P.: Induction of HLA Mutations by Chemical Mutagens in Human Lymphoid Cells	437
Pizarro, O., Vergara, U., and Figueroa, F.: A Study of Histocompatibility-2 Antigens in Wild Mice from Santiago, Chile	57
Pollard, L.W.: <i>see</i> Benedict, A.A. <i>et al.</i>	199
Poole, T.W.: <i>see</i> Silvers, W.K. <i>et al.</i>	85
Potter, M.: <i>see</i> Weigert, M. <i>et al.</i>	401

Powell, K.R.: <i>see</i> Spencer, M.J. <i>et al.</i>	365
Puget, A.: <i>see</i> Cazenave, P. <i>et al.</i>	489
Rajan, T.V.: H-2 Antigen Variants in a Cultured Heterozygous Mouse Leukemia Cell Line	105
Rigiero, C.: <i>see</i> Palm, J. <i>et al.</i>	79
Rohde, H.: <i>see</i> Nowack, H. <i>et al.</i>	117
Rosén, A.: <i>see</i> Zeuthen, J. <i>et al.</i>	567
Ruppelt, W.: <i>see</i> Grosse-Wilde, H. <i>et al.</i>	481
Rychlíková, M.: <i>see</i> Cukrová, V. <i>et al.</i>	531
Sato, H., Itakura, K., and Boyse, E.A.: Location of <i>Lyb-2</i> on Mouse Chromosome 4	591
Schmid, F.R.: <i>see</i> Osofsky, S.G. <i>et al.</i>	195
Schultz, J.S., Beals, T.F., and DeMott-Friberg, R.: Tissue Graft Rejection in Mice. II. Graft Survival Across <i>H-2</i> Regional Barriers	315
Schuppen, W.: <i>see</i> Grosse-Wilde, H. <i>et al.</i>	481
Silver, D.M., and Lane, D.P.: Identification of the Gene Locus Controlling Dominant Nonresponsiveness to F-Antigen	295
Silvers, W.K., Murphy, G., and Poole, T.W.: Studies on the H-Y Antigen in Rats	85
Silvers, W.K.: <i>see</i> Elkins, W.L.	245
Šimonová, D.: <i>see</i> Gregorová, S. <i>et al.</i>	301
Siskind, G.W.: <i>see</i> Kim, Y.T.	463
Shen, F.: <i>see</i> Taylor, B.A.	597
Sherman, M.I.: <i>see</i> Ostrand-Rosenberg, S. <i>et al.</i>	127
Smith, S.M., Ness, D.B., Talcott, J.A., and Grumet, F.C.: Genetic Control of IgM Responses to (T,G)-A—L. <i>H-2</i> and <i>Ig-1</i> Linkage	221
Soderland, C.: <i>see</i> Pious, D. <i>et al.</i>	437
Solheim, B.G.: <i>see</i> Kaakinen, A. <i>et al.</i>	205
Spencer, M.J., Cherry, J.D., Powell, K.R., Mickey, M.R., Terasaki, P.I., Marcy, S.M., and Sumaya, C.V.: Antibody Responses Following Ru- bella Immunization Analyzed by HLA and ABO Types	365
Stallings, V.: <i>see</i> Hyman, R.	171
Stankus, R.P., and Leslie, G.A.: Interspecies and Interantigenic Evaluation of a Crossreactive Rat Idiotypic	233
Stanton, T.H.: <i>see</i> Flaherty, L. <i>et al.</i>	101
Streilein, J.W.: Clark Humble: An Immunolegend for Our Time	1
Strosberg, A.D.: Multiple Expression of Rabbit Allotypes: The Tip of the Iceberg?	499
Sumaya, C.V.: <i>see</i> Spencer, M.J. <i>et al.</i>	365
Talcott, J.A.: <i>see</i> Smith, S.M. <i>et al.</i>	221
Taylor, B.A., Shen, F.: Location of <i>Lyb-2</i> on Mouse Chromosome 4: Evidence from Recombinant Inbred Strains	597
Terasaki, P.I.: <i>see</i> Spencer, M.J. <i>et al.</i>	365
Timpl, R.: <i>see</i> Nowack, H. <i>et al.</i>	117
Thompson, B.H.: <i>see</i> Osofsky, S.G. <i>et al.</i>	195
Thorsby, E.: <i>see</i> Kaakinen, A. <i>et al.</i>	205

Tongio, M.M.: <i>see</i> Hauptmann, G. <i>et al.</i>	557
Vadas, M.A., Miller, J.F.A.P., Whitelaw, A.M., and Gamble, J.R.: Regulation by the H-2 Gene Complex of Delayed Type Hypersensitivity . . .	137
Vergara, U.: <i>see</i> Pizarro, O. <i>et al.</i>	57
Warner, C.M.: <i>see</i> Newton, R.C.	449
Weigert, M., and Potter, M.: Antibody Variable-Region Genetics: Summary and Abstracts of the Homogeneous Immunoglobulin Workshop VII . . .	401
Wettstein, P.J., and Houghton, G.: The Genetic Control of the Immune Response to Murine Histocompatibility Antigens I. The Response to H-4 Alloantigens	65
Whitelaw, A.M.: <i>see</i> Vadas, M.A. <i>et al.</i>	137
Wicker, L.S.: <i>see</i> Harmon, R.C. <i>et al.</i>	601
Zeiger, A.R.: <i>see</i> Merryman, C.F. <i>et al.</i>	373
Zeuthen, J., Friedrich, U., Rosén, A., and Klein, E.: Structural Abnormalities in Chromosome 15 in Cell Lines with Reduced Expression of Beta-2 Microglobulin	567
Zink, G.L., and Heyner, S.: The Production of Non- <i>H-2</i> Histocompatibility Alloantibodies in the Mouse	257
Zinkernagel, R.M., and Klein, J.: <i>H-2</i> -Associated Specificity of Virus-Immune Cytotoxic T Cells from <i>H-2</i> Mutant and Wild-Type Mice: M523 (<i>H-2K^{ka}</i>) and M505 (<i>H-2K^{bd}</i>) Do, M504 (<i>H-2D^{da}</i>) and M506 (<i>H-2K^{fa}</i>) Do Not Crossreact with Wild-Type <i>H-2K</i> or <i>H-2D</i>	581

Virus-Specific T-Cell Sensitization

Requirements for Vaccinia Virus-Specific T-Cell Sensitization *in vivo**

Hildegund C.J. Ertl, Rainer H.W. Gerike, and Ulrich H. Koszinowski

Hygiene Institut der Universität Göttingen,
Kreuzbergring 57, D-34 Göttingen, Federal Republic of Germany

Abstract. Syngeneic, semiallogeneic, or allogeneic spleen lymphocytes were transferred into *nu/nu* BALB/c mice, which were infected with vaccinia virus. Specific sensitization of transferred thymus-derived cells was determined *in vivo* by mean survival time and virus titer in the spleen six days after infection, and *in vitro* by cell-mediated cytolysis of vaccinia virus-infected syngeneic target cells. Virus-specific sensitization took place only after transfer of syngeneic or semiallogeneic spleen lymphocytes; allogeneic lymphocytes had no influence on mean survival time or virus titer and showed no virus-specific cytolytic activity *in vitro*. Infection of mice with vaccinia virus-strain WR, Elstree, DIs, or DIs-infected syngeneic fibroblasts resulted in the generation of virus-specific effector cells, while injection of a high amount of inactivated virus particles caused no sensitization. These results suggest H-2 homology for production of virus-specific effector cells. Propagation of virus is not necessary, since early surface antigens, combined with syngeneic H-2 antigens, suffice for sensitization of cytolytic T lymphocytes.

Introduction

The infection of mice with certain viruses such as the LCM virus (Zinkernagel and Doherty 1974), poxviruses (Gardner *et al.* 1975, Koszinowski and Thomssen 1975), or Sendai virus (Ertl and Koszinowski 1976) results in the generation of cytolytic T lymphocytes, which are able to kill *in vitro* cells infected with the virus used for sensitization. The activity of CTLs sensitized against viruses, chemically modified cells (Shearer *et al.* 1975), minor histocompatibility antigens (Bevan 1975, Gordon *et al.* 1975) is restricted to attacker- and target-cell homol-

* Abbreviations used in this paper are as follows: CMC, cell-mediated cytolysis; CTL, cytolytic T lymphocyte; LCM, lymphocytic choriomeningitis; MHC, major histocompatibility complex; MST, mean survival time; T cell, thymus-derived cell; TCID₅₀, 50 percent tissue culture infective dose.

ogy of the *K* or *D* end of the major histocompatibility complex. Two hypotheses have been postulated to explain this H-2 restriction (Doherty and Zinkernagel 1975). The physiological interaction theory needs a T cell-specific antigen, such as a viral surface antigen, and an interaction between identical H-2 structures on effector and target cell for recognition and lysis. The altered self theory proposes an alteration of H-2 antigenic determinants by virus infection or by chemical treatment of cells. Recent findings in chimeric mice (Zinkernagel 1976) favor the latter theory. Another hypothesis, which proposes a "dual recognition" by two T-cell receptors specific for a (modified) *K*- or *D*-region product and a viral surface antigen as a requirement for target cell lysis, should be considered. Experiments, which show an inhibition of CMC by antiviral antibodies (Koszinowski and Thomssen 1975) are in agreement with this concept.

The role of H-2 antigenic structures in the sensitization phase is still unknown. Data reported here were obtained after infection of *nu/nu* BALB/c mice which were inoculated with syngeneic, semiallogeneic, or allogeneic spleen cells. A specific sensitization, measured *in vivo* by the mean survival time and virus titer in the spleens and *in vitro* by cytolytic activity of CTL, was dependent on the homology of the *K* and *D* ends of the *H-2* complex between lymphocytes and infected cells.

To obtain further information about the viral antigens for sensitization of T cells, mice were infected with different virus strains or with inactivated vaccinia virus particles. The three strains we used differed in the expression of viral surface antigens on infected cells. Early vaccinia surface antigens were sufficient for induction of specific CTL *in vivo*.

Materials and Methods

Animals. Mice of the inbred strains C3H (*H-2^k*), DBA/2 (*H-2^d*), A/J (*H-2^a*), and *nu/nu* Balb/c (*H-2^d*) at the age of 6–10 weeks were used throughout. They were purchased from Bomholtgard, Ry, Denmark.

Viruses. Vaccinia virus, strain WR and strain Elstree (Lister strain), was propagated in Vero cells (monkey kidney cells) and used in a concentration of $10^{5.5}$ TCID₅₀/ml. Strain DIs, a conditional lethal mutant of the DIE strain (Tagaya *et al.* 1961), kindly provided by Dr. Y. Ueda, Tokyo, Japan, was propagated in 12-day-old fertile chicken eggs at 37°C for 2 days. DIs virus was used in a concentration of 1×10^5 TCID₅₀/ml.

Virus Purification. Virus was purified by the method of Joklik (1962).

Virus Titration. WR and Elstree viruses were titrated on Vero cells. Titration for DIs was done on primary chicken fibroblasts (Tagaya *et al.* 1974). TCID₅₀ was determined according to the method of Reed and Muench (1938).

Virus Inactivation. Vaccinia virus infectivity was inactivated without loss of antigenicity by incubation at 56°C for 120 minutes, interrupted 3 times by a short sonication procedure.

Target Cells. L-929 fibroblasts (*H-2^k*), obtained from Dr. Lehmann-Grube, Hamburg, and mastocytoma P-815–X-2 cells were cultivated in Eagle's minimal essential medium, supplemented with 10% inactivated calf serum and 100 µg/ml streptomycin and penicillin.

Infection and Radioactive Labeling of Target Cells. About 5×10^5 L-929 cells growing as monolayer cultures in glass bottles were incubated with 10 ml vaccinia virus suspension on a rocker platform for 2 hours. The virus suspension was then replaced by fresh serum-free medium, and about 16–18 hours later, cells were trypsinized and incubated with $100 \mu\text{Ci } ^{51}\text{Cr}$ (sodium chromate, Amersham, Buchler, Braunschweig, 100 to 200 mCi/mg Cr No CJS1P) in a volume of 1 ml for 1 hour. After washing 3 times to remove unbound radioactivity, the cells were used in cytolytic assays. P-815 cells were infected with about 5 TCID₅₀ per cell for 2 hours, washed twice, and labeled with ^{51}Cr for 1 hour.

Effector Cells. Mice were infected intraperitoneally with $10^{5.5}$ TCID₅₀ (strains WR and Elstree), 10^5 TCID₅₀ (strain DIs), inactivated vaccinia virus (10^{10} TCID₅₀ before inactivation), or 1×10^6 L-929 cells infected with DIs virus. Nude BALB/c mice were inoculated intravenously with 5×10^7 Ficoll-purified spleen cells of C3H, DBA/2, or A/J mice. Six days later, spleens were removed and lymphocytes were prepared.

Cell-Mediated Cytolysis (CMC). The activity of spleen lymphocytes was tested in an 18-hour Cr-release assay as described earlier (Koszinowski and Thomssen 1975). Briefly, 5×10^6 spleen cells from immunized or normal mice were incubated in microplates with 5×10^4 normal or vaccinia virus-infected ^{51}Cr -labeled target cells in a volume of 0.2 ml at 37°C in a humidified atmosphere with 7% CO₂. Eighteen hours later, supernatant and cell pellet were separated and the percentage of Cr release was determined. Percentage of specific lysis was calculated using the following formula:

$$\text{Percent specific lysis} = \text{Percent Cr release in presence of sensitized lymphocytes} \\ - \text{Percent Cr release in presence of normal lymphocytes}$$

Results

Mean Survival Time of Nude Mice Infected with Vaccinia Virus and Inoculated with Syngeneic, Semiallogeneic, or Allogeneic Spleen Lymphocytes

Normal inbred mice survive a vaccinia virus infection without obvious symptoms. Nude mice, which are characterized by a congenital lack of thymus-derived cells (T cells) died about two weeks after the infection. Inoculation of nude mice with 5×10^7 allogeneic spleen lymphocytes did not prolong the survival time. Only syngeneic (or semiallogeneic) spleen cells extended the MST significantly (Fig. 1).

Vaccinia Virus Titer in the Spleens of Nude Mice Six Days After Vaccinia Virus Infection

Groups of three *nu/nu* BALB/c mice were infected with $1 \times 10^{5.5}$ TCID₅₀ vaccinia virus (strain WR) and inoculated with 5×10^7 syngeneic (DBA/2), semiallogeneic (A), or allogeneic (C3H) spleen lymphocytes. Six days later, spleens were removed and the virus content was estimated by titration on Vero cell monolayers. As is shown in Table I, spleens of nude mice infected with vaccinia virus contained about $10^{3.2}$ TCID₅₀ virus. Spleens of infected animals, which were inoculated with allogeneic spleen lymphocytes, contained comparable amounts of virus, while in spleens of mice which received syngeneic or semiallo-




Fig. 1. Groups of *15nu/nu* BALB/c mice were infected with $1 \times 10^{5.5}$ TCID₅₀ vaccinia virus and injected simultaneously with 5×10^7 allogeneic (C3H), or syngeneic spleen lymphocytes. Controls received medium or allogeneic spleen cells alone. ^aLethality of untreated mice

Table 1. Reduction of Vaccinia Virus Titer in the Spleens of Nude Mice^a

Origin of Spleens	Virus Titer
Nude mice (<i>H-2^d</i>) + $10^{5.5}$ TCID ₅₀ Vaccinia virus	$10^{3.2}$ TCID ₅₀
Nude mice (<i>H-2^d</i>) + $10^{5.5}$ TCID ₅₀ Vaccinia virus + A (<i>H-2^a</i>) spleen cells	0
Nude mice (<i>H-2^d</i>) + $10^{5.5}$ TCID ₅₀ Vaccinia virus + C3H (<i>H-2^k</i>) spleen cells	$10^{2.6}$ TCID ₅₀
Nude mice (<i>H-2^d</i>) + $10^{5.5}$ TCID ₅₀ Vaccinia virus + DBA/2 (<i>H-2^d</i>) spleen cells	0

^a The vaccinia virus content of spleen cells of three *nu/nu* BALB/c mice infected six days previously with $1 \times 10^{5.5}$ TCID₅₀ vaccinia virus and injected with 1×10^7 syngeneic, semiallogeneic, or allogeneic spleen lymphocytes was estimated by titration on Vero cells. TCID₅₀ was determined by the method of Reed and Muench (1938).

genic spleen lymphocytes, no infectious virus was demonstrable six days after infection.

Cell-Mediated Cytolysis by Lymphocytes of nu/nu BALB/c Mice Infected with Vaccinia Virus and Substituted with Syngeneic, Semiallogeneic, or Allogeneic Spleen Lymphocytes

Nude mice were not able to produce cytolytic lymphocytes after infection with vaccinia virus (Table 2). After transfer of 5×10^7 allogeneic spleen lymphocytes, no virus-specific killer cells against virus-infected target cells were generated;

Table 2. Cell-Mediated Cytolysis of Normal and Vaccinia Virus-Infected P-815 Target Cells^a

Origin of Lymphocytes	Percent Specific Lysis	
	P-815	P-815-Infected
<i>nu/nu</i> (<i>H-2^d</i>) → vaccinia virus	1.3 ± 2.3	4.4 ± 4.3
<i>nu/nu</i> (<i>H-2^d</i>) + A (<i>H-2^a</i>) spleen cells	2.1 ± 1.4	4.3 ± 2.3
<i>nu/nu</i> (<i>H-2^d</i>) + A (<i>H-2^a</i>) spleen cells → vaccinia virus	2.9 ± 1.0	17.7 ± 6.1
<i>nu/nu</i> (<i>H-2^d</i>) + C3H (<i>H-2^k</i>) spleen cells	11.1 ± 4.5	0.1 ± 4.1
<i>nu/nu</i> (<i>H-2^d</i>) + C3H (<i>H-2^k</i>) spleen cells → vaccinia virus	9.8 ± 2.4	0.5 ± 4.0
<i>nu/nu</i> (<i>H-2^d</i>) + DBA/2 (<i>H-2^d</i>) spleen cells	2.6 ± 2.5	0.7 ± 2.2
<i>nu/nu</i> (<i>H-2^d</i>) + DBA/2 (<i>H-2^d</i>) spleen cells → vaccinia virus	1.3 ± 0.6	22.8 ± 3.9

^a The cytolytic activity of spleen lymphocytes of *nu/nu* BALB/c mice infected six days previously with vaccinia virus and injected with 1×10^7 syngeneic, semiallogeneic, or allogeneic spleen cells was tested on normal and infected P-815 target cells. Assay time: 18 hours. Attacker cell to target cell ratio: 100:1.

only a weak allograft reaction against noninfected P-815 cells could be observed. Syngeneic or semiallogeneic-transferred spleen lymphocytes were able to kill only vaccinia virus-infected target cells and had no cytolytic effect on noninfected targets. Using normal and vaccinia virus-infected L-929 cells as controls, no specific lysis by any group of CTL was observed.

Role of Different Vaccinia Virus Antigens in Sensitization of Antiviral CTL

Groups of three C3H mice were infected by intraperitoneal injection of $1 \times 10^{5.5}$ TCID₅₀ vaccinia virus, strain WR or Elstree; $1 \times 10^{5.0}$ TCID₅₀ DIs virus; heat-inactivated purified virus (1×10^{10} TCID₅₀ before inactivation); or 1×10^7 DIs-infected L-929 fibroblasts.

The three vaccinia virus strains vary in the expression of viral surface antigens. Strain WR, our standard test strain, propagates in mouse cells and expresses early and late surface antigens on the infected cells. Strain Elstree is

Table 3. CMC by Lymphocytes from Mice Sensitized with Different Vaccinia Virus Strains and Viral Antigens^a

Origin of Lymphocytes	Percent Specific Lysis of WR-Infected L-929 cells
C3H → $1 \times 10^{5.5}$ TCID ₅₀ WR	45.0 ± 2.6
C3H → $1 \times 10^{5.5}$ TCID ₅₀ Elstree	18.8 ± 1.2
C3H → $1 \times 10^{5.0}$ TCID ₅₀ DIs	27.6 ± 2.4
C3H → inactivated vaccinia virus	1.4 ± 1.9
C3H → L-929, DIs-infected	16.9 ± 1.3

^a The cytolytic activity of spleen lymphocytes of C3H mice infected six days previously with $1 \times 10^{5.5}$ TCID₅₀ vaccinia virus, strain WR or Elstree; $1 \times 10^{5.0}$ TCID₅₀ DIs virus; 1×10^7 DIs-infected L-929 cells; or 1×10^{10} TCID₅₀ heat-inactivated vaccinia virus (WR) was tested on vaccinia virus (WR)-infected L-929 target cells. Assay time: 18 hours. Attacker cell to target cell ratio: 100:1.

defective in the production of early surface antigens. Strain DIs does not propagate in mouse cells but expresses early surface antigens.

Lymphocytes of mice infected with any of these virus strains were able to kill vaccinia virus-infected syngeneic target cells (L-929 infected with WR virus, Table 3). Also, the injection of DIs virus-infected syngeneic fibroblasts led to the production of CTL, while the injection of a high dose of inactivated purified virus particles caused no antiviral sensitization of T lymphocytes.

Discussion

T cell-mediated immunity is essential for recovery from poxvirus infection (Blanden 1974, Blanden *et al.* 1975). Macrophages, B cells, or antibodies do not seem to suffice. This was shown in nude mice, which are characterized by a congenital lack of thymus-derived lymphocytes. In contrast to normal mice, these animals died about one to two weeks after a vaccinia virus infection.

One important role of sensitized T lymphocytes may be the control of virus multiplication. T cells are probably not able to reduce the number of virus particles (Blanden 1971). There is some evidence for virus clearance by macrophages, which are activated by sensitized immune lymphocytes (Koszinowski *et al.* 1975). Infected cells, which express early viral surface antigens, are lysable by CTL (Koszinowski and Ertl 1976). Early viral surface antigens are synthesized about one hour after the infection, while the release of complete infective virus particles requires 16 to 20 hours. CTL prevent viral DNA synthesis and virus multiplication by attacking cells bearing early viral surface antigens.

For sensitization of T lymphocytes, early viral surface antigens were sufficient, as has been proposed by other authors (Ueda and Tagaya 1973). Infection of mice with a high dose of inactivated virus was ineffective, so the stimulus for *in vivo* induction of cytolytic T lymphocyte production seems to be the virus-infected cell, rather than the free virion. Structural antigens may be essential for activation of B cells, which produce neutralizing antibodies. The role of late surface antigens, which are expressed on the cell surface during viral DNA synthesis, remains unexplained under the experimental conditions, since the Elstree strain is only partially defective in production of early surface antigens (Ito and Barron 1972).

The cytolytic activity of T cells is characterized by two restrictions. First, their action is virus-specific; no crossreactivity occurs between such different viruses as LCM virus, vaccinia virus, or Sendai virus (Ertl and Koszinowski 1976). Second, for efficient lysis, donors of the cytolytic T lymphocytes and infected cells must be identical at the *K* or *D* region of the *H-2* gene complex, since CTL discriminate even point mutations within the *K* region (Doherty *et al.* 1976). *H-2* homology is also necessary for the production of virus-specific effector cells, as was shown by transfer of syngeneic, semiallogeneic, or allogeneic spleen cells into vaccinia virus-infected nude mice.

These data agree with the modified self hypothesis. One may speculate that early viral surface antigens modify *H-2* antigenic structures. Recirculating T lymphocytes control the integrity of *H-2* antigens; cells bearing altered or un-

known (allogeneic or xenogeneic) H-2 antigens lead to clonal expansion of T lymphocytes, which eliminate these cells.

Transfer of syngeneic or semiallogeneic lymphocytes into infected nude mice caused increased MST and virus clearance *in vivo*. *In vitro*, the transferred lymphocytes lysed virus-infected syngeneic target cells. Induction of virus-specific CTLs across the H-2 barrier was possible in chimeric mice (Zinkernagel 1976). In contrast to lymphocytes, which were transferred into allogeneic nude mice, CTLs from chimeric mice are tolerant to the allogeneic target cells, which may partially explain the differing results. The *in vitro* activity of intolerant allogeneic sensitized CTLs was rather weak. Neither virus-infected allogeneic nor normal or infected syngeneic target cells were lysed. Transfer of allogeneic spleen cells had no influence on the progress of virus infection *in vivo*: MST was not prolonged and virus titer in these mice was not reduced significantly. One reason for the failure of protection by transferred allogeneic T cells may be the lack of generation of cytolytic T cells. Furthermore, it may indicate that collaboration between T cells and other immune mechanisms, which cause clearance of infective virus under syngeneic or semiallogeneic conditions, is impossible in a complete allogeneic situation.

References

- Bevan, M.J.: Interaction antigens detected by cytotoxic T cells with the major histocompatibility complex as modifier. *Nature (Lond.)* 256:419-421, 1975
- Blanden, R.V.: Mechanisms of recovery from a generalized viral infection: mouse pox. II. Passive transfer of recovery mechanisms with immune lymphoid cells. *J. Exp. Med.* 133:1074-1089, 1971
- Blanden, R.V.: T-cell response to viral and bacterial infection. *Transplant. Rev.* 19:56-88, 1974
- Blanden, R.V., Bower, N.A., Pang, T., Garder, I.D., and Parish, C.R.: Effect to thymus independent (B) cells and the H-2 gene complex and anti-viral function of immune thymus derived (T) cells. *Aust. J. Exp. Biol. Med. Sci.* 53:187-192, 1975
- Doherty, P.C. and Zinkernagel, R.M.: A biological role for the major histocompatibility antigens. *Lancet* 1:1406-1409, 1975
- Doherty, P.C., Blanden, R.V., and Zinkernagel, R.M.: Specificity of virus-immune effector T-cells for H-2K or H-2D compatible interactions: implications for H-2 antigen diversity. *Transplant. Rev.* 29:89-105, 1976
- Ertl, H. and Koszinowski, U.: Cell-mediated cytotoxicity against Sendai virus infected cells. *Z. Immun. Forsch.* 152:128-140, 1976
- Gardner, I.D., Bower, N.A., and Blanden, R.V.: Cell-mediated cytotoxicity against ectromelia virus infected target cells. III. Role of the H-2 gene complex. *Eur. J. Immunol.* 5:122-127, 1975
- Gordon, R.D., Simpson, E., and Samelson, L.E.: *In vitro* cell-mediated immune responses to the male specific (H-Y) antigen in mice. *J. Exp. Med.* 142:1108-1120, 1975
- Ito, M. and Barron, A.L.: Studies on a strain of Vaccinia virus defective in surface antigen production. *Proc. Soc. Exp. Biol. Med.* 140:374-377, 1972
- Joklik, W.H.: The purification of four strains of poxvirus. *Virology* 18:9-18, 1962
- Koszinowski, U. and Ertl, H.: Role of early viral surface antigens in cellular immune response to Vaccinia virus. *Eur. J. Immunol.* 6:679-683, 1976
- Koszinowski, U. and Thomssen, R.: Target cell dependent T-cell mediated lysis of vaccinia virus-infected cells. *Eur. J. Immunol.* 5:245-251, 1975
- Koszinowski, U., Kruse, F., and Thomssen, R.: Interactions between Vaccinia virus and sensitized macrophages *in vitro*. *Arch. Virology* 48:335-345, 1975

- Reed, L.J. and Muench, H.W.: A simple method of estimating fifty percent endpoints. *Am. J. Hyg.* 27:493-497, 1938
- Shearer, G.M., Rehn, G.R., and Garbarino, C.A.: Cell-mediated lympholysis of trinitrophenyl modified autologous lymphocytes. Effector cell specificity to modified cell surface components controlled by the *H-2K* and *H-2D* regions of the murine major histocompatibility complex. *J. Exp. Med.* 141:1348-1364, 1975
- Tagaya, I., Hitamura, T., and Sano, Y.: A new mutant of dermopoxvirus. *Nature* 192:381-382, 1961
- Tagaya, I., Amona, H., and Yussa, T.: Improved plaque assay of a mutant of Vaccinia virus, strain DIs in chick embryo cell cultures. *Jap. J. Med. Sci. Biol.* 27:245-248, 1974
- Ueda, Y. and Tagaya, I.: Induction of skin resistance to Vaccinia virus in rabbits by Vaccinia-soluble early antigens. *J. Exp. Med.* 138:1033-1043, 1973
- Zinkernagel, R.M.: Virus-specific T-cell-mediated cytotoxicity across the H-2 barrier to virus-altered alloantigens. *Nature (Lond.)* 261:187-190, 1976
- Zinkernagel, R.M. and Doherty, P.C.: Restriction of in vitro T-cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. *Nature* 248:701-702, 1974

Received August 10, 1976